Kiora Pharmaceuticals, Inc. (KPRX)
Automate Your Wheel Strategy on KPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including KPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KPRX
- Rev/Share 0.0047
- Book/Share 5.6202
- PB 0.5373
- Debt/Equity 0.0067
- CurrentRatio 5.1392
- ROIC -0.4536
- MktCap 9192457.0
- FreeCF/Share -1.844
- PFCF -1.1821
- PE -1.0567
- Debt/Assets 0.0047
- DivYield 0
- ROE -0.4281
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Published: June 03, 2025 by: Newsfile Corp
Sentiment: Neutral
Total potential deal value of $110 million plus royalties Kiora to receive an immediate $1.25 million exclusive option fee If the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory, and commercial milestones, plus tiered royalties on sales Encinitas, California--(Newsfile Corp. - June 3, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has granted Senju Pharmaceutical Co., Ltd. (Senju) an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases.
Read More
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
Published: May 09, 2025 by: Newsfile Corp
Sentiment: Neutral
Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key first quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.
Read More
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Published: April 04, 2025 by: Newsfile Corp
Sentiment: Neutral
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M.
Read More
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
Published: March 25, 2025 by: Newsfile Corp
Sentiment: Neutral
Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation.
Read More
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Published: February 13, 2025 by: Newsfile Corp
Sentiment: Neutral
Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
Read More
About Kiora Pharmaceuticals, Inc. (KPRX)
- IPO Date 2015-02-13
- Website https://www.kiorapharma.com
- Industry Biotechnology
- CEO Dr. Brian M. Strem Ph.D.
- Employees 12